COX-2 and PPARγ as alternative targets for endometriosis.

OLIVARES CARLA; RICCI ANALÍA; BILOTAS MARIELA; BARAÑAO ROSA INÉS; MERESMAN GABRIELA

Montpellier

Congreso; 11th World Congress on Endometriosis; 2011

World Endometriosis Society

The pursue for new treatment options for endometriosis patients is constant. Previous reports demonstrated that inhibiting cyclooxygenase (COX)-2 and activating peroxisome proliferator-activated receptor (PPAR)γ has antiproliferative, proapoptotic and antiangiogenic effects in different in vivo and in vitro cancer models. Objectives: Study the effect of the inhibition of COX-2 and/or the activation of PPARγ on the development of endometriotic like lesions in a murine model. Methods: Two months old BALB/c mice were surgically induced with endometriosis. After 28 days of daily treatment with vehicle (100µl), celecoxib (200mg/kg), rosiglitazone (0.16mg/kg) or their combination, animals were sacrificed; developed lesions were counted, measured, excised and fixed in formalin. All treatments were administered by esophageal gavage. Paraffin embedded specimens were cut into 5µm sections for posterior apoptosis determination by TdT-mediated dUTP Nick-End Labeling (TUNEL) technique, cellular proliferation rate by immunohistochemistry of the proliferation cell nuclear antigen (PCNA) and vascularized area determination performing CD31 and CD34 immunohistochemistry. Results: The number of developed lesions was significantly reduced by celecoxib and the combined treatment (p